PharmaFocus Today – Page 15 – media

Innovent Biologics’ Enzeshu was approved for marketing, becoming China’s first targeted drug for all patients with platinum-resistant ovarian cancer

Recently , Innovent’s innovative drug subsidiary, Innovent, announced that its new generation of anti-angiogenesis (anti-VEGF antibody) first-class biological new drug Enzeshu (generic name: Suvicitamab for injection) developed in China has been officially approved for marketing by the China National Medical Products Administration. Enzeshu is approved for the treatment of recurrent ovarian cancer, fallopian tube cancer or primary peritoneal cancer in adults who have received no more than one systemic treatment after platinum resistance in combination with paclitaxel, liposome doxorubicin or topotecan. It is reported that Enzeshu is the first targeted drug in my country to obtain indications for the entire population of platinum-resistant ovarian cancer, breaking the dilemma of limited treatment options in this field. In recent years, the innovative transformation of the old pharmaceutical company Innovent Biologics has begun to show results. The company currently has 10 innovative drugs on the market, and 8 of them have been approved ...
- Source: drugdu
- 66
- July 14, 2025
CStone Pharmaceuticals and Istituto Gentili Enter into European Commercialization Collaboration

Recently , CStone Pharmaceuticals announced that it has reached an exclusive strategic cooperation with Istituto Gentili (hereinafter referred to as Gentili) on the commercialization of Sugemalimab in Western Europe and the United Kingdom. Gentili has obtained the exclusive commercialization rights of Sugemalimab in 23 countries, and CStone Pharmaceuticals will receive a payment of up to US$192.5 million, including an initial payment, registration and sales milestone payments, and a revenue share of nearly 50% of the net sales of Sugemalimab in the authorized area. This cooperation shows that CStone Pharmaceuticals’ products have been recognized in the international market, which will help enhance its influence in the field of global cancer treatment. In the long run, this cooperation will enhance investors’ confidence in the company’s future growth and lay the foundation for the company to further expand its overseas market. https://www.nbd.com.cn/articles/2025-07-08/3936641.html
- Source: drugdu
- 53
- July 14, 2025
The rise of PD-1/VEGF triple antibodies

With Kangfang Biopharma’s successful challenge to PD-1 monoclonal antibody with Ivoside, tumor immunotherapy (IO) has rapidly evolved to the 2.0 era. PD-(L)1/VEGF bispecific antibodies have been snapped up by MNCs, and PD-(L)1/VEGF trispecific antibodies have gradually become a research and development trend, indicating that tumor treatment is accelerating towards multi-target synergy. Recently, CStone Pharmaceuticals announced the latest clinical progress of its independently developed potential first-in-class/best-in-class CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody). The drug has balanced monovalent PD-1 and CTLA-4 binding arms and bivalent VEGFA binding arms, which can produce strong multi-target synergistic effects and preferentially target tumor tissues to reduce systemic toxicity. The global multi-center Phase I/II clinical study of CS2009 is actively recruiting patients in Australia and China, and plans to expand to the United States for Phase II enrollment. Currently, the trial enrollment is very rapid, and the number of patients is expected to exceed 100 by the end of ...
- Source: drugdu
- 55
- July 14, 2025
The leading domestic pharmaceutical company for general cell therapy of Parkinson’s disease has obtained tens of millions of yuan in market-based financing within a few months!

According to industrial and commercial information, in May 2025, Roche Biopharmaceuticals (Suzhou/Shanghai) Co., Ltd. (Roche Accelerator Member) has completed a new round of market-oriented financing . The new financing came from Jianfa Emerging Investment, Suzhou Angel Fund, Xinxi Capital, and Qisheng Capital. Just a few months ago, in October 2024, Shize Bio officially announced the completion of more than 100 million yuan in B1 round of market-oriented financing : the B1 round of financing was led by Tailong/Taikun Capital, co-invested by Qisheng Capital and Tianhui Capital, and additional investments from old shareholders such as Frees Capital, Qiming Venture Partners, Lilly Asia Fund, and Sequoia China. The B1 round of financing will be used to improve Shize Bio’s clinical-grade iPS-derived cell drug pipeline for the treatment of neurological diseases, further conduct clinical research, and promote multiple registered clinical trials. During the overall downturn of the pharmaceutical industry from 2022 to 2025, ...
- Source: drugdu
- 51
- July 14, 2025
Henlius HLX43 has been approved by multiple countries to conduct an international multi-center Phase II clinical trial in NSCLC, leading the global development of PD-L1 ADC

Recently, Henlius has made another important progress in the global development of its innovative programmed death-ligand 1 (PD-L1) antibody-drug conjugate (ADC) injection HLX43. The product has been approved by the China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to conduct an international multicenter Phase II clinical study for advanced non-small cell lung cancer (NSCLC), and the first subject has been dosed in China. No similar ADC product targeting PD-L1 has been approved for marketing in the world, and HLX43 is the world’s first PD-L1 ADC to enter Phase II clinical trials. According to the latest data from GLOBOCAN, lung cancer is the cancer with the highest morbidity and mortality in the world. In 2022, there will be more than 2.48 million new cases of lung cancer worldwide, accounting for 12.4% ...
- Source: drugdu
- 87
- July 14, 2025
A subsidiary of United Pharmaceuticals received FDA approval for clinical trials of innovative drugs

On July 10, United Pharmaceutical (03933) issued an announcement, announcing that its wholly-owned subsidiary United Biotech received approval from the U.S. FDA on July 4, 2025 to register its Class 1 innovative drugUBT37034 injection is used in clinical trials for the indication of overweight or obesity. The drug was developed by Federal Biotechnology and has independent intellectual property rights.It is a new type of peptide receptor agonist that can reduce body weight by selectively acting on neuropeptide Y2 receptors. The announcement mentioned that preclinical animal model studies of UBT37034 showed that it can significantly reduce body weight when used in combination with GLP-1 analogs. The company said it will continue to focus on new product research and development, enhance its competitiveness and creativity in the biopharmaceutical industry, and is expected to create greater benefits for the company and its shareholders. https://finance.eastmoney.com/a/202507103453263675.html
- Source: drugdu
- 63
- July 14, 2025
SINOPHARM New Drug Application Accepted

On July 10, SINOPHARM (01177) announced that the Group’s independently developed CDK2/4/6 inhibitor Cumocillin Capsules “TQB3616” combined with Fulvestrant Injection for previously untreated HR-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer has been submitted to the Center for Drug Evaluation of the China National Medical Products Administration for new indications for marketing approval and has been accepted. The approval of the first-line indication application further confirms the broad potential of this combination therapy in different treatment stages of advanced breast cancer. In addition, the new drug application for Cumosili submitted by the Group in July 2024 has also been accepted by the CDE for use in combination with Fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer that has been previously treated with endocrine therapy. The announcement mentioned that breast cancer is one of the most common malignant tumors in women, of which HR+/HER2- breast cancer ...
- Source: drugdu
- 64
- July 14, 2025
The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted

Simcere Pharma (02096) announced on the evening of July 8 that the company and Hong Kong Connect BiopharmaceuticalsInnovative drugs developed by pharmaceutical companiesThe New Drug Application (NDA) for Ledeqibaimab has been accepted by the China National Medical Products Administration (NMPA) and is intended for the treatment of atopic dermatitis in adults and adolescents. Ledeqibaimab is a fully human monoclonal antibody targeting IL-4Rα (a common subunit of IL-4 and IL-13 receptors). By blocking the functions of IL-4 and IL-13, the drug can effectively inhibit the Th2-type inflammatory pathway, thus providing a possible treatment for Th2-related inflammatory diseases such as atopic dermatitis and asthma. According to reports, Connect Biopharma is a global clinical-stage biopharmaceutical company focused on the development of innovative therapies for inflammatory diseases. In addition to atopic dermatitis, the company is conducting global studies on Ledeqibaimab for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) ...
- Source: drugdu
- 60
- July 10, 2025
Kanghua Biopharma terminates cooperation in tuberculosis and rabies vaccine research and development

On July 8, Kanghua Bio(300841) issued an announcement that the company reached an agreement with Chengdu Xinran Bochuang Biotechnology Co., Ltd. (Xinran Bochuang) and decided to terminate the research and development project on tuberculosis mRNA vaccine, and at the same time terminate the subsequent research and development cooperation on rabies mRNA vaccine and herpes zoster mRNA vaccine. This decision was made based on the company’s established independent R&D team for the mRNA technology platform and the completion of the transfer of collaborative R&D results, combined with the company’s overall business development plan. The announcement mentioned that Sinopharm has completed the relevant research on rabies mRNA vaccine and shingles mRNA vaccine, and delivered the results to the company, and the company has paid the corresponding amount; however, the tuberculosis mRNA vaccine project has not yet been launched and no expenses or work results have been generated. In the agreement to terminate ...
- Source: drugdu
- 63
- July 10, 2025
Small nucleic acid therapy challenges GLP-1 giants

RNAi technology targets the core shortcomings of GLP-1 drugs by precisely regulating the expression of obesity-related genes. With the disruptive advantage of “reducing fat without losing muscle”, RNAi therapy is strongly challenging the “hegemony” of the GLP-1 market worth hundreds of billions! 01The wave of small nucleic acid therapy has arrived Small nucleic acid therapy, especially siRNA (small interfering RNA) technology, with its unique gene silencing mechanism and continuously innovative delivery technology, jointly promotes the expansion of treatment areas from rare diseases to chronic diseases, leading the third wave of innovation in the biomedicine field. From the technical principle, siRNA achieves precise gene silencing through the RNA interference (RNAi) mechanism. In its double-stranded structure, the guide strand (antisense strand) is loaded into the RISC complex and then specifically binds to the target mRNA and guides its degradation, thereby blocking the expression of pathogenic proteins; while the guest strand (sense strand) ...
- Source: drugdu
- 62
- July 10, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.